Urothelial Carcinoma: Novel Therapies and Strategies to Improve Patient Outcomes
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with urothelial carcinoma.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Treatment Options for Patients with Bladder Cancer
A number of new treatment options for different stages of bladder cancer are on the horizon, which will make education about the data behind these therapies and how they might be used in clinical practice important. Of interest, a number of treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer (NMIBC) are currently being evaluated in clinical trials, and systemic therapy options for muscle-invasive and metastatic disease have rapidly expanded.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer
Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.
Category
  • Bladder Cancer
  • Genitourinary Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date September 29, 2022
NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation